446 related articles for article (PubMed ID: 22424434)
1. Biomarkers in inflammatory bowel disease: current practices and recent advances.
Iskandar HN; Ciorba MA
Transl Res; 2012 Apr; 159(4):313-25. PubMed ID: 22424434
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
Iijima H; Shinzaki S; Tsujii M; Takehara T
Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
Kim BG; Kim YS; Kim JS; Jung HC; Song IS
Dis Colon Rectum; 2002 Aug; 45(8):1062-9. PubMed ID: 12195191
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.
Bennike T; Birkelund S; Stensballe A; Andersen V
World J Gastroenterol; 2014 Mar; 20(12):3231-44. PubMed ID: 24696607
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Iborra M; Beltrán B; Nos P
Gastrointest Endosc Clin N Am; 2016 Oct; 26(4):641-56. PubMed ID: 27633593
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Modalities for Inflammatory Bowel Disease: Serologic Markers and Endoscopy.
Clark C; Turner J
Surg Clin North Am; 2015 Dec; 95(6):1123-41, v. PubMed ID: 26596918
[TBL] [Abstract][Full Text] [Related]
7. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.
Lewis JD
Gastroenterology; 2011 May; 140(6):1817-1826.e2. PubMed ID: 21530748
[TBL] [Abstract][Full Text] [Related]
8. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
[TBL] [Abstract][Full Text] [Related]
9. Advances in clinical laboratory tests for inflammatory bowel disease.
Nakamura RM; Matsutani M; Barry M
Clin Chim Acta; 2003 Sep; 335(1-2):9-20. PubMed ID: 12927679
[TBL] [Abstract][Full Text] [Related]
10. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
[TBL] [Abstract][Full Text] [Related]
11. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG; Gomollon F
Inflamm Bowel Dis; 2009 Nov; 15(11):1746-54. PubMed ID: 19363798
[TBL] [Abstract][Full Text] [Related]
12. Proteomic insights on the metabolism in inflammatory bowel disease.
Pisani LF; Moriggi M; Gelfi C; Vecchi M; Pastorelli L
World J Gastroenterol; 2020 Feb; 26(7):696-705. PubMed ID: 32116417
[TBL] [Abstract][Full Text] [Related]
13. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
14. New proteomic approaches for biomarker discovery in inflammatory bowel disease.
Roda G; Caponi A; Benevento M; Nanni P; Mezzanotte L; Belluzzi A; Mayer L; Roda A
Inflamm Bowel Dis; 2010 Jul; 16(7):1239-46. PubMed ID: 20127998
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
16. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
[TBL] [Abstract][Full Text] [Related]
17. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
Quinton JF; Sendid B; Reumaux D; Duthilleul P; Cortot A; Grandbastien B; Charrier G; Targan SR; Colombel JF; Poulain D
Gut; 1998 Jun; 42(6):788-91. PubMed ID: 9691915
[TBL] [Abstract][Full Text] [Related]
18. Serologic markers in inflammatory bowel disease (IBD).
Nakamura RM; Barry M
MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
[TBL] [Abstract][Full Text] [Related]
19. Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an Academic Medical Center.
Gupta A; Derbes C; Sellin J
Inflamm Bowel Dis; 2005 Oct; 11(10):898-902. PubMed ID: 16189419
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children.
Gupta SK; Fitzgerald JF; Croffie JM; Pfefferkorn MD; Molleston JP; Corkins MR
Inflamm Bowel Dis; 2004 May; 10(3):240-4. PubMed ID: 15290918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
